Figure 3.

Sitagliptin prevents the upregulation of DPP-IV content in the kidney induced by diabetes. (a) The protein levels of DPP-IV were assessed in total kidney cell lysates by Western Blotting in ZDF (+/+) and ZDF (fa/fa) nontreated or treated with sitagliptin. The Western Blots presented are representative of each group of animals. (b) Representative confocal images for each group of animals showing DPP-IV (green) immunoreactivity and nuclear staining with DAPI (blue) in kidney sections (b1), as well as immunoreactivity quantification for DPP-IV (a2). Bars = 20 μm. Data are expressed as percentage of control and represent the mean ± SEM (n ≥ 6 per group); ***P < 0.001 significantly different from control; ^## P < 0.01 significantly different from diabetic.